Oramed Pharmaceuticals Inc
WKN: A1CTNU / ISIN: US68403P2039Oramed Pharmaceuticals Inc.
| eröffnet am: | 28.03.07 13:46 von: | OttomanRosendahl |
| neuester Beitrag: | 04.07.25 17:17 von: | woroda |
| Anzahl Beiträge: | 991 | |
| Leser gesamt: | 321712 | |
| davon Heute: | 83 | |
bewertet mit 5 Sternen |
||
|
|
||
sinkt weiter
ormp.png (verkleinert auf 55%)
Oramed Remains Strong With Near and Long-Term Catalysts
https://www.gurufocus.com/news/531649/...-near-and-longterm-catalysts
Trotzdem hoffe ich dass die nächsten Monate mal sichtbare Ergebnisse zeigen und der Kurs nachhaltig nach oben dreht ...
Solange chill and Grill
https://clinicaltrials.gov/ct2/show/NCT02535715?term=oramed&rank=1
In February 2017 , we completed a Phase IIa dose finding clinical trial which was initiated in October 2016. This randomized, double-blind trial was conducted on 32 type 2 adult diabetic patients in order to define the optimal dosing of ORMD-0801 moving forward . We anticipate receiving the clinical study report in the second quarter of calendar year 2017.
In March 2017, we initiated a six month toxicology study for use of our oral insulin capsule for a longer period than previously performed, as preparation for our future Phase III study. We anticipate receiving the results in the third quarter of calendar year 2017.
In September 2013, we submitted a pre-IND package to the FDA for ORMD-0901, our oral exenatide capsule, for a Phase II clinical trial on healthy volunteers and type 2 diabetic patients. In August 2015, we began a non-FDA approved clinical trial on type 2 diabetic patients. The trial was completed during the second quarter of calendar year 2016 and indicated positive results as it showed ORMD-0901 to be safe and well tolerated and also demonstrated encouraging efficacy data . We completed a toxicology study in March 2017 and anticipate receiving the results during the second quarter of calendar year 2017 and expect to file an IND and move directly into a pharmacokinetics study followed by a large Phase II trial in the United States.
Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule
http://www.nasdaq.com/press-release/...-analog-capsule-20170627-00578
Als vorwärts!
Diesmal ist das Datum in der "Corporate Presentation" noch nicht dem neuen Monat angepasst worden. Ein Zeichen auf ein update?
wird auch demnächst angepasst. Derzeit:
dddd.png (verkleinert auf 39%)
qqqq.png (verkleinert auf 24%)
31. August Meeting mit der FDA wegen Phase 3, auch nicht schlecht!
http://www.nasdaq.com/symbol/ormp/press-releases
11.07.2017:
Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
12.07.2017: Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017
18.07.2017: Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
http://www.nasdaq.com/press-release/...or-oral-insulin-20170905-00217
Habe nur keine News gefunden.
Weiß jemand etwas ?
Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule
http://www.nasdaq.com/press-release/...h-with-its-oral-20171114-00613
Q4 19: Phase III study projected initiation (projected completion Q2 21) (Seite 4)
Gibt die Aktie nichts mehr her ? Keine Perspektiven ?!